港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

中醫藥概念

700.747

+9.0061.30%

漲家數：9

跌家數：2

平家數：- -

市盈率：- -

高：701.246

開：691.031

低：691.031

收：691.741

資料載入中...

總覽新聞資訊

現代中藥集團預計年度淨溢利800萬至1200萬元

【現代中藥集團(01643.HK)發盈警預計2024年度淨溢利下降至800萬元至1200萬元】現代中藥集團(01643.HK)發佈公告，預期集團將於截至2024年12月31日止年度取得金額介乎人民幣800萬元至1200萬元的淨溢利，而截至2023年12月31日止年度則取得約人民幣4880萬元的淨溢利。

現代中藥集團(01643)發盈警預計2024年度淨溢利下降至800萬元至1200萬元

智通财经网

現代中藥集團發盈警預計2024年度淨溢利下降至800萬元至1200萬元

智通财经网

白雲山阿託伐他汀鈣化學原料藥上市申請獲批

白雲山(00874)分公司收到化學原料藥上市申請批准通知書

白雲山：分公司收到阿託伐他汀鈣化學原料藥上市申請批准通知書

每日经济新闻

白雲山(600332.SH)：阿託伐他汀鈣化學原料藥上市申請獲批准

同仁堂國藥03月06日主力淨流入52萬元散户資金拋售

白雲山03月06日主力淨流入156萬元散户資金拋售

培力農本方(01498)股價顯著上升11.321%，現價港幣$0.59

阿斯达克财经

白雲山(00874.HK)子公司獲頒高新技術企業證書可享內地企業優惠政策

阿斯达克财经

山東綠葉製藥有限公司申請II類會議

白雲山子公司《藥品生產許可證》變更

格隆汇资讯

白雲山(00874)：明興藥業收到《藥品生產許可證》

白雲山子公司廣藥總院通過高新技術企業重新認定

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK1606/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1606"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1606\",,,,,undefined,":{"symbol":"BK1606","market":"HK","secType":"PLATE","nameCN":"中醫藥概念","latestPrice":700.74695,"timestamp":1741248510268,"preClose":691.7414,"halted":0,"volume":63209374,"delay":0,"changeRate":0.013019,"change":9.005554,"pbRate":0.895723,"amount":197296923,"amplitude":0.014768,"prevYearClose":739.0471,"fiveDayClose":712.542,"twentyDayClose":694.139,"turnoverRate":0.004207,"marketCap":77759367696,"floatMarketCap":49454110480,"peRate":10.170414},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1606\",,,,,undefined,":{"symbol":"BK1606","high":701.2463,"amplitude":0.014768,"preClose":691.7414,"low":691.0309,"pbRate":"0.895723","latestPrice":700.74695,"volume":63209374,"delay":0,"open":691.0309,"prevYearClose":739.0471,"prevWeekClose":689.34,"prevMonthClose":689.34,"prevQuarterClose":739.047,"fiveDayClose":712.542,"twentyDayClose":694.139,"sixtyDayClose":753.126,"secType":"PLATE","market":"HK","turnoverRate":0.004207,"peRate":10.170414,"marketCap":77759367696,"floatMarketCap":49454110480,"timestamp":1741248510268,"nameCN":"中醫藥概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1606\",,,,undefined,":{"bkCode":"BK1606","up":9,"down":2,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1606\",pageSize:16,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2517152335","title":"現代中藥集團預計年度淨溢利800萬至1200萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517152335","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517152335?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 20:36","pubTimestamp":1741264562,"startTime":"0","endTime":"0","summary":"格隆汇3月6日丨 现代 中药 集团 (01643.HK)公告，集团预计截至2024年12月31日止年度录得金额介于人民币8.0百万元至人民币12.0百万元的净溢利，而截至2023年12月31日止年度则录得约人民币48.8百万元的净溢利。净溢利有所下降乃主要归因于1）于2024年2月至5月期间因制剂车间进行修缮工程引致的暂时停产及受国家新政策影响以及活跃客户数量下降导致收益减少；及2)拆除制剂车间导致的物业、厂房及设备处置损失。尽管如此，董事会预计集团整体营运及现金流量不会受到重大不利影响。于本公告日期，集团拥有充足的手头现金应付其现时业务所需。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306205042a262744a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306205042a262744a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01643","BK1191","BK1606"],"gpt_icon":0},{"id":"2517415972","title":"【現代中藥集團(01643.HK)發盈警 預計2024年度淨溢利下降至800萬元至1200萬元】現代中藥集團(01643.HK)發佈公告，預期集團將於截至2024年12月31日止年度取得金額介乎人民幣800萬元至1200萬元的淨溢利，而截至2023年12月31日止年度則取得約人民幣4880萬元的淨溢利。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517415972","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517415972?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 20:27","pubTimestamp":1741264062,"startTime":"0","endTime":"0","summary":"现代中药集团(01643.HK)发布公告，预期集团将于截至2024年12月31日止年度取得金额介乎人民币800万元至1200万元的净溢利，而截至2023年12月31日止年度则取得约人民币4880万元的净溢利。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/06202748572714.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["01643","BK1191","BK1606"],"gpt_icon":0},{"id":"2517238159","title":"現代中藥集團(01643)發盈警 預計2024年度淨溢利下降至800萬元至1200萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517238159","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517238159?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 20:24","pubTimestamp":1741263841,"startTime":"0","endTime":"0","summary":"智通财经APP讯，现代中药集团 发布公告，预期集团将于截至2024年12月31日止年度取得金额介乎人民币800万元至1200万元的净溢利，而截至2023年12月31日止年度则取得约人民币4880万元的净溢利。尽管如此，董事会预计集团整体营运及现金流量不会受到重大不利影响。于本公告日期，集团拥有充足的手头现金应付其现时业务所需。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258750.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["01643","BK1606","BK1191"],"gpt_icon":0},{"id":"2517159441","title":"現代中藥集團發盈警 預計2024年度淨溢利下降至800萬元至1200萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517159441","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517159441?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 20:24","pubTimestamp":1741263841,"startTime":"0","endTime":"0","summary":"智通财经APP讯，现代中药集团(01643)发布公告，预期集团将于截至2024年12月31日止年度取得金额介乎人民币800万元至1200万元的净溢利，而截至2023年12月31日止年度则取得约人民币4880万元的净溢利。净溢利有所下降乃主要归因于：于2024年2月至5月期间因制剂车间进行修缮工程引致的暂时停产及受国家新政策影响以及活跃客户数量下降导致收益减少;拆除制剂车间导致的物业、厂房及设备处置损失。尽管如此，董事会预计集团整体营运及现金流量不会受到重大不利影响。于本公告日期，集团拥有充足的手头现金应付其现时业务所需。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306202717963c2c25&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306202717963c2c25&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1606","01643"],"gpt_icon":0},{"id":"2517158861","title":"白雲山阿託伐他汀鈣化學原料藥上市申請獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2517158861","media":"北京商报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517158861?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 18:49","pubTimestamp":1741258183,"startTime":"0","endTime":"0","summary":"北京商报讯（记者王寅浩）3月6日，白云山发布公告称，近日公司分公司白云山化学制药厂收到国家药品监督管理局签发的阿托伐他汀钙《化学原料药上市申请批准通知书》。该药物为羟甲基戊二酰辅酶A还原酶抑制剂，主要用于治疗原发性高胆固醇血症和其他相关疾病。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202503063338670898.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503063338670898.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["00874","BK1197","BK1521","BK1515","BK1191","BK1606"],"gpt_icon":0},{"id":"2517132738","title":"白雲山(00874)分公司收到化學原料藥上市申請批准通知書","url":"https://stock-news.laohu8.com/highlight/detail?id=2517132738","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517132738?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 18:08","pubTimestamp":1741255698,"startTime":"0","endTime":"0","summary":"智通财经APP讯，白云山 发布公告，近日，广州白云山医药集团股份有限公司分公司广州白云山医药集团股份有限公司白云山化学制药厂 收到国家药品监督管理局签发的阿托伐他汀钙《化学原料药上市申请批准通知书》。经查询，目前国内阿托伐他汀钙原料药的主要生产厂家有齐鲁制药有限公司、天方药业有限公司、宜昌东阳光长江药业股份有限公司等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258641.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","600332","BK1191","BK0196","BK0175","BK1197","00874","BK1606","BK0096","BK0012","BK0239","BK0183","BK0070","BK0188","BK0028","BK0097","BK1521"],"gpt_icon":0},{"id":"2517131106","title":"白雲山：分公司收到阿託伐他汀鈣化學原料藥上市申請批准通知書","url":"https://stock-news.laohu8.com/highlight/detail?id=2517131106","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517131106?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 17:18","pubTimestamp":1741252718,"startTime":"0","endTime":"0","summary":"每经AI快讯，3月6日，白云山(600332.SH)公告称，公司分公司白云山化学制药厂收到国家药监局签发的阿托伐他汀钙《化学原料药上市申请批准通知书》。阿托伐他汀钙为HMG-CoA还原酶抑制剂，主要用于治疗高胆固醇血症等。该原料药的获批，有助于丰富白云山化学制药厂心脑血管类产品的种类，但对公司当期业绩无重大影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202503063338598582.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503063338598582.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","00874","BK1191","BK1521","BK1197","BK1606"],"gpt_icon":0},{"id":"2517139065","title":"白雲山(600332.SH)：阿託伐他汀鈣化學原料藥上市申請獲批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2517139065","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517139065?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 17:18","pubTimestamp":1741252682,"startTime":"0","endTime":"0","summary":"智通财经APP讯，白云山(600332.SH)公告，公司分公司广州白云山医药集团股份有限公司白云山化学制药厂(简称“白云山化学制药厂”)收到国家药品监督管理局签发的阿托伐他汀钙《化学原料药上市申请批准通知书》。公告显示，阿托伐他汀钙为羟甲基戊二酰辅酶A(HMG-CoA)还原酶抑制剂。主要通过抑制HMGCoA还原酶的合成，从而抑制体内胆固醇的合成，降低血清低密度脂蛋白胆固醇、甘油三酯的含量。主要适应症为原发性高胆固醇血症、混合型高脂血症、高甘油三酯血症、纯合子家族性高胆固醇血症及防治动脉粥样硬化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258586.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","00874","BK0097","BK1197","BK1521","BK1606","BK1515","600332","BK0070","BK0028","BK0188","BK0196","BK0239","BK0175","BK0012","BK0183","BK0096"],"gpt_icon":0},{"id":"2517113600","title":"同仁堂國藥03月06日主力淨流入52萬元 散户資金拋售","url":"https://stock-news.laohu8.com/highlight/detail?id=2517113600","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517113600?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 16:16","pubTimestamp":1741249017,"startTime":"0","endTime":"0","summary":"03月06日, 同仁堂国药股价涨0.86%，报收8.20元，成交金额614万元，换手率0.09%，振幅1.11%，量比0.63。同仁堂国药今日主力资金净流入52万元，上一交易日主力净流出88万元。该股近5个交易日下跌0.24%，主力资金累计净流出590万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流出466万元，其中净流出天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306170039abeb146a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306170039abeb146a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03613","BK1606","BK1191"],"gpt_icon":0},{"id":"2517613687","title":"白雲山03月06日主力淨流入156萬元 散户資金拋售","url":"https://stock-news.laohu8.com/highlight/detail?id=2517613687","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517613687?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 16:15","pubTimestamp":1741248915,"startTime":"0","endTime":"0","summary":"03月06日, 白云山股价涨1.01%，报收17.92元，成交金额3559万元，换手率0.91%，振幅1.24%，量比1.35。白云山今日主力资金净流入156万元，上一交易日主力净流出0万元。该股近5个交易日下跌0.88%，主力资金累计净流出200万元；近20日主力资金累计净流出28万元，其中净流出天数为5日。该股主力净额占比0.04%，港股市场排名265/2651。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306165127a26227b9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306165127a26227b9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1521","BK1191","BK1197","BK1606","BK1515","00874"],"gpt_icon":0},{"id":"2517090739","title":"培力農本方(01498)股價顯著上升11.321%，現價港幣$0.59","url":"https://stock-news.laohu8.com/highlight/detail?id=2517090739","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517090739?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 11:45","pubTimestamp":1741232700,"startTime":"0","endTime":"0","summary":"[上升股]培力农本方(01498) 股价在上午11:45比前收市价显著上升11.321%，现股价为港币$0.59。至目前为止，今日最高价为$0.59，而最低价为$0.54。总成交量为3.6万股，总成交金额为港币$2.012万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152549604_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152549604_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2503065370/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["01498","BK1191","BK1606"],"gpt_icon":0},{"id":"2517971082","title":"白雲山(00874.HK)子公司獲頒高新技術企業證書 可享內地企業優惠政策","url":"https://stock-news.laohu8.com/highlight/detail?id=2517971082","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517971082?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 08:53","pubTimestamp":1741222380,"startTime":"0","endTime":"0","summary":"白云山(00874.HK) 公布，旗下子公司广药总院已通过高新技术企业重新认定，并收到由广东省科学技术厅、广东省财政厅、国家税务总局广东省税务局联合颁发的《高新技术企业证书》，公告指，广药总院通过高新技术企业认定后，根据国家的相关规定，自获得高新技术企业认定后连续三年内可享受国家关于高新技术企业的相关优惠政策，即按15%的税率缴纳企业所得税。另外，白云山去年已按照15%的所得税税率计缴该公司所得税。本次广药总院获得《高新技术企业证书》不会对白云山当期经营业绩产生重大影响。(js/w)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-05 16:25。)AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190128164618458_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190128164618458_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1422532/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK0070","BK1191","BK0183","BK0188","BK1515","BK0175","BK1197","BK0028","BK0096","600332","00874","BK0196","BK1521","BK0097","BK1606","BK0239","BK0012"],"gpt_icon":0},{"id":"2517208089","title":"山東綠葉製藥有限公司申請II類會議","url":"https://stock-news.laohu8.com/highlight/detail?id=2517208089","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517208089?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 06:18","pubTimestamp":1741213084,"startTime":"0","endTime":"0","summary":"山东绿叶制药有限公司，成立于1994年，位于烟台市，是一家以从事医药制造业为主的企业。通过天眼查大数据分析，山东绿叶制药有限公司共对外投资了20家企业，参与招投标项目1868次，知识产权方面有商标信息306条，专利信息214条，此外企业还拥有行政许可119个。主要股东信息显示，山东绿叶制药有限公司由烟台绿叶医药控股（集团）有限公司持股100%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/06061848551489.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1583","BK1606","BK1191","02186"],"gpt_icon":0},{"id":"2517903659","title":"白雲山子公司《藥品生產許可證》變更","url":"https://stock-news.laohu8.com/highlight/detail?id=2517903659","media":"格隆汇资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517903659?lang=zh_tw&edition=fundamental","pubTime":"2025-03-05 18:53","pubTimestamp":1741172002,"startTime":"0","endTime":"0","summary":"格隆汇3月5日丨白云山(00874.HK)公告，近日，广州白云山医药集团股份有限公司(以下简称“本公司”)子公司广州白云山明兴制药有限公司(以下简称“明兴药业”)收到广东省药品监督管理局核准签发的《药品生产许可证》，同意明兴药业核减生产地址及相应的车间生产线、生产范围。明兴药业白云厂区实现规模化运作，本次核减生产车间、生产线和生产范围，有利于进一步整合生产资源、优化产能布局，继续保持稳定的生产能力，满足市场需求。本次获得《药品生产许可证》，对本公司当期业绩无重大影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305185324963a9b73&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305185324963a9b73&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1197","BK1515","00874","BK1521","BK1191","BK1606"],"gpt_icon":0},{"id":"2517973009","title":"白雲山(00874)：明興藥業收到《藥品生產許可證》","url":"https://stock-news.laohu8.com/highlight/detail?id=2517973009","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517973009?lang=zh_tw&edition=fundamental","pubTime":"2025-03-05 18:52","pubTimestamp":1741171941,"startTime":"0","endTime":"0","summary":"智通财经APP讯，白云山(00874)公布，近日，公司子公司广州白云山明兴制药有限公司(以下简称“明兴药业”)收到广东省药品监督管理局核准签发的《药品生产许可证》，同意明兴药业核减生产地址及相应的车间生产线、生产范围。公告称，明兴药业白云厂区实现规模化运作，本次核减生产车间、生产线和生产范围，有利于进一步整合生产资源、优化产能布局，继续保持稳定的生产能力，满足市场需求。本次获得《药品生产许可证》，对公司当期业绩无重大影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258136.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0196","BK0097","600332","00874","BK1515","BK0188","BK1197","BK0012","BK0070","BK1521","BK0239","BK1606","BK0175","BK0028","BK0096","BK1191","BK0183"],"gpt_icon":0},{"id":"2517299033","title":"白雲山子公司廣藥總院通過高新技術企業重新認定","url":"https://stock-news.laohu8.com/highlight/detail?id=2517299033","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517299033?lang=zh_tw&edition=fundamental","pubTime":"2025-03-05 18:51","pubTimestamp":1741171909,"startTime":"0","endTime":"0","summary":"格隆汇3月5日丨白云山公告，近日，广州白云山医药集团股份有限公司子公司广州医药研究总院有限公司已通过高新技术企业重新认定，并收到由广东省科学技术厅、广东省财政厅、国家税务总局广东省税务局联合颁发的《高新技术企业证书》。本次广药总院获得《高新技术企业证书》不会对本公司当期经营业绩产生重大影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305185149a2607f58&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305185149a2607f58&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1521","BK1191","BK1197","00874","BK1515","BK1606"],"gpt_icon":0}],"pageSize":16,"totalPage":4,"pageCount":1,"totalSize":50}]}}